Sodium Oxybate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
REM Sleep Behavior Disorder
Conditions
REM Sleep Behavior Disorder, Parkinson Disease
Trial Timeline
Sep 10, 2019 → Feb 1, 2022
NCT ID
NCT04006925About Sodium Oxybate
Sodium Oxybate is a approved stage product being developed by Jazz Pharmaceuticals for REM Sleep Behavior Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT04006925. Target conditions include REM Sleep Behavior Disorder, Parkinson Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04006925 | Approved | Completed |
| NCT00931164 | Phase 1/2 | Completed |
| NCT00594256 | Phase 2 | Completed |
| NCT00514995 | Phase 2/3 | Completed |
| NCT00506974 | Approved | Completed |
| NCT00641186 | Phase 2 | Completed |
Competing Products
20 competing products in REM Sleep Behavior Disorder